# Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

> PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22644981-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22644981-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22644981-exenatide-v1.json
- Content SHA-256: `ab29b9bbb09d8cc5dd3e4e87158bf6d77150e09ae7fae1880aea4bbf867d99b9`

## Claims and source pins

### Headline

Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

### Summary

PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

### Paragraph 1

PubMed lists PMID 22644981 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Case Reports, Journal Article, with publication-date metadata of 2012-06-15 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`](#source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a))

## Sources

<a id="source-pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a"></a>
- **Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. · retained source version 1:2026-01-28:current:fdde71a7649a1e8bc2a077f249cc29070823950a8de8b4d8960898257e4d5f99** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22644981/) (`pubmed-observation-pmid-22644981-2026-01-28-fdde71a7649a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22644981-exenatide-v1.json SHA-256: ab29b9bbb09d8cc5dd3e4e87158bf6d77150e09ae7fae1880aea4bbf867d99b9.